Introduction

Among the rarest craniofacial syndromes, Pfeiffer syndrome is distinguished by its unique combination of skull, facial, and limb abnormalities. Its cause lies in subtle mutations of growth factor receptor genes that can affect the structure of the human face.

Pfeiffer syndrome is a rare inherited disorder characterised by premature fusion of the skull and face. Common features include underdevelopment of the midface, broad thumbs and great toes, and the partial joining of the hands and feet.²

Also referred to as type V acrocephalosyndactyly, craniofacial-skeletal-dermatologic dysplasia, or Noack syndrome², it is the second most common condition within the acrocephalosyndactyly syndromes, following Apert syndrome.¹

The syndrome exhibits significant clinical heterogeneity and can range from mild forms with normal intelligence to severe phenotypes associated with neurological impairment and early mortality.^1,2

History and epidemiology

First described in 1964 by Rudolf Pfeiffer, the syndrome was identified in eight individuals across three generations of a single family.¹ The original cases were characterised by acrocephalosyndactyly (abnormal head growth), hypertelorism (abnormally distant eye sockets), antimongoloid slant of the eyes, and normal intelligence. Male-to-male transmission in this family supported an autosomal dominant mode of inheritance.¹ Pfeiffer syndrome affects approximately 1 in 100,000 newborns.¹ The syndrome shows complete penetrance, but symptoms can vary even among affected family members.¹

Aetiology and genetic basis

Pfeiffer syndrome arises from mutations in the fibroblast growth factor receptor genes FGFR1 and FGFR2.^1,2 These genes produce proteins that act as receptors, critical for the regulation of cell proliferation and differentiation during embryonic development, particularly in the formation of bone tissue.^1,2 Mutations lead to prolonged receptor signalling, which triggers premature fusion of cranial sutures and abnormal development of digits.^1,2

Type 1 Pfeiffer syndrome, the classic form, can result from mutations in either FGFR1 or FGFR2, whereas types 2 and 3 are primarily associated with FGFR2 mutations.^1,2 Most FGFR2 mutations linked to severe forms include p.W290C, p.Y340C, p.C342R, and p.S351C.^1,2 Conversely, the FGFR1 mutation p.P252R typically produces less severe symptoms.^1,2 Advanced paternal age has been identified as a risk factor for de novo mutations, consistent with the autosomal dominant inheritance pattern.^1,2 Each child of an affected parent carries a 50% chance of inheriting the disorder.^1,2

Clinical features

Pfeiffer syndrome is classified into three clinical subtypes based on severity:

Type 1 (Classic)

This syndrome is the mildest form and is characterised by craniofacial (changes to the bones of the skull and face) and limb abnormalities, including brachycephaly (shortened head) due to bicoronal synostosis (early fusion of skull bones), midface hypoplasia (underdevelopment of the midface), hypertelorism (widely spaced eyes), broad thumbs and great toes, and variable syndactyly. Cognitive development is typically normal.¹

Type 2

This syndrome is more severe, and features include craniosynostosis, often resulting in a cloverleaf skull (Kleeblattschädel). Individuals may haveextreme ocular proptosis (bulging eyes), midface hypoplasia (underdevelopment of midface), elbow ankylosis (stiff elbows), and neurological impairments.¹ Hydrocephalus and other visceral anomalies such as hydronephrosis, pelvic kidneys, and hypoplastic gallbladder may also be present.²

Type 3

Shares many characteristics with type 2 but without the cloverleaf skull deformity. Severe neurological and developmental complications are common, and early mortality risk is high.^1,2 Patients often display craniosynostosis (one or more joints fuse too early), proptosis, hypertelorism, maxillary deficiency, and a beaked nose.³ The thumbs and great toes may be wide and bent away from other digits, sometimes with brachydactyly or syndactyly (abnormal short fingers or toes).³ 

Type I is associated with FGFR1 and FGFR2 mutations, while types II and III involve FGFR2 mutations.³ Genetic heterogeneity (genetic variation) is significant, with approximately 5% of type I cases resulting from a gain-of-function P252R mutation in FGFR1.³ This mutation increases receptor activity and activation, producing a milder phenotype.³ Types II and III, usually caused by FGFR2 mutations, have more severe phenotypes and worse prognoses.³

Fibroblast growth factor (FGF) signalling plays a crucial role in development and disease. FGFs regulate proliferation, migration, differentiation, angiogenesis, embryogenesis (various processes at the cellular level) and wound healing.³ There are 18 mammalian FGF types grouped into six subfamilies, and FGFRs are tyrosine kinase receptors with distinct extracellular, transmembrane, and intracellular domains.³ FGFR mutations can cause the receptor to become active without receiving its normal signals, leading to conditions such as congenital syndromes, skeletal disorders and hearing loss.³ Dysregulated FGF signalling is also implicated in cancer and other pathologies, and therapeutic approaches targeting FGFs are under investigation.³

Diagnosis

Diagnosis is primarily clinical, based on the combination of craniosynostosis, brachysyndactyly, and characteristic craniofacial features. Genetic confirmation requires mutation analysis of FGFR1 (exon 7), FGFR2 (exons 8 and 10), and, in some cases, FGFR3 (exon 7).^1,2 Prenatal diagnosis is possible via ultrasound, which may reveal cranial and limb abnormalities such as hypertelorism, proptosis, broad thumbs, or syndactyly. Molecular testing is particularly useful in recurrent cases or when the causative mutation is known.^1,2

Differential diagnosis

Pfeiffer syndrome must be distinguished from other craniosynostosis syndromes, including Apert, Crouzon, Muenke, Saethre-Chotzen, and Jackson-Weiss syndromes.^1,2 Apert syndrome is distinguished by the absence of a cloverleaf skull and proptosis. Crouzon syndrome lacks hand and foot anomalies characteristic of Pfeiffer syndrome. Muenke syndrome involves a specific FGFR3 mutation with overlapping craniofacial features, while Antley-Bixler syndrome can mimic type 2 Pfeiffer but is autosomal recessive and primarily affects visceral structures.^1,2

Management

Management of Pfeiffer syndrome requires a multidisciplinary approach, involving neurosurgeons, craniofacial surgeons, otolaryngologists, ophthalmologists, paediatricians, and genetic counsellors. The main objectives are to relieve intracranial pressure, correct craniofacial deformities, and optimise functional outcomes.^1,2

Surgical interventions are usually staged. Early procedures include suturectomy within the first year of life to allow brain growth and reduce intracranial pressure. Extensive cranial vault reconstructions, such as fronto-orbital advancement, LeFort osteotomies, or monobloc procedures, may be performed later to correct skull and midfacial abnormalities.^1,2

Hydrocephalus may require cerebrospinal fluid shunting, and severe airway compromise may necessitate tracheostomy. Postoperative care often includes prolonged ventilatory support in intensive care, particularly in cases with tracheal anomalies.^1,2

Prognosis

The prognosis varies according to subtype. Type 1 typically has a favourable outcome with normal intelligence and lifespan. Types 2 and 3 carry a higher risk of neurodevelopmental delay, severe complications, and early mortality. Aggressive multidisciplinary intervention can improve outcomes, even in severe phenotypes.^1,2,3

Complications

Potential complications include cognitive impairment, hydrocephalus, airway obstruction, proptosis-related keratitis, aspiration pneumonia, and seizures. Timely surgical interventions and continuous follow-up are crucial for reducing morbidity and improving quality of life.^1,2,3

Genetic counselling and patient education

Because Pfeiffer syndrome is primarily autosomal dominant, genetic counselling is essential for affected families. Counselling should address recurrence risks, potential for de novo mutations, and implications of advanced paternal age. Families must be educated about the variability of clinical expression, the need for multiple staged surgeries, and long-term care requirements, including developmental and educational interventions.^1,2

FAQs

What causes Pfeiffer syndrome?

It is caused by mutations in the FGFR1 and FGFR2 genes, which lead to abnormal activation of fibroblast growth factor signalling pathways.

How many types of Pfeiffer syndrome exist?

There are three: Type I (classic), Type II (cloverleaf skull), and Type III (severe form without cloverleaf skull).

What are the key features of Pfeiffer syndrome?

Craniosynostosis (abnormal head growth), midface hypoplasia (underdeveloped skeleton of cheek, jaw, and eyes), proptosis (bulging of eyes), hypertelorism (abnormally distant eye sockets), broad thumbs and great toes, and sometimes syndactyly (fused fingers).

How is the syndrome diagnosed?

Through clinical evaluation and confirmed by genetic testing for FGFR1 or FGFR2 mutations.

Can Pfeiffer syndrome be treated?

While there’s no cure, surgical correction of skull and facial deformities, along with supportive therapies, can greatly improve function and appearance.

What is the prognosis of Pfeiffer syndrome?

Type I generally has a normal lifespan and intelligence, while Types II and III have more severe symptoms and a poorer prognosis.

Summary

Pfeiffer syndrome is a complex craniofacial disorder with wide-ranging clinical manifestations, such as craniosynostosis (abnormal head growth), midface hypoplasia (underdeveloped skeleton of cheek, jaw, and eyes), proptosis (bulging of eyes), hypertelorism (abnormally distant eye sockets), broad thumbs and great toes, and sometimes syndactyly (fused fingers), and genetic heterogeneity.

This syndrome results from mutations in the FGFR1 and FGFR2 genes, which alter fibroblast growth factor signalling, a key pathway in bone and tissue development. The disruption leads to premature cranial suture fusion, broad thumbs, great toes, and distinctive facial features, such as midface hypoplasia and proptosis. The severity of these symptoms varies among the three clinical subtypes (types I, II, and III). Type I generally has a good prognosis, while types II and III are associated with severe complications and higher mortality.

Early recognition, molecular confirmation, and a coordinated multidisciplinary approach are critical for optimising patient outcomes. Surgical correction, management of associated complications, and long-term support significantly improve the quality of life for affected individuals. Genetic counselling and education empower families to make informed decisions regarding care and future pregnancies.

Comprehensive management involves early surgical interventions to relieve intracranial pressure and correct facial deformities, along with continuous follow-up for airway, vision, and developmental support. Genetic counselling plays a central role in understanding inheritance patterns, recurrence risks, and available prenatal diagnostic options. Continued research into FGFR signalling and targeted therapies holds promise for more effective and less invasive future treatments.